Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Total Liabilities (2019 - 2025)

Keros Therapeutics filings provide 7 years of Total Liabilities readings, the most recent being $34.9 million for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 21.3% to $34.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $34.9 million, a 21.3% decrease, with the full-year FY2025 number at $34.9 million, down 21.3% from a year prior.
  • Total Liabilities hit $34.9 million in Q4 2025 for Keros Therapeutics, down from $39.2 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $55.7 million in Q1 2025 to a low of $7.8 million in Q2 2021.
  • Median Total Liabilities over the past 5 years was $30.2 million (2023), compared with a mean of $28.7 million.
  • Biggest five-year swings in Total Liabilities: surged 163.82% in 2023 and later dropped 21.3% in 2025.
  • Keros Therapeutics' Total Liabilities stood at $12.1 million in 2021, then skyrocketed by 143.09% to $29.4 million in 2022, then rose by 28.8% to $37.8 million in 2023, then grew by 17.25% to $44.3 million in 2024, then dropped by 21.3% to $34.9 million in 2025.
  • The last three reported values for Total Liabilities were $34.9 million (Q4 2025), $39.2 million (Q3 2025), and $50.4 million (Q2 2025) per Business Quant data.